Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (785)	12/3/1997 1:06:00 PM
From: Agenda	Read Replies (1) \| Respond to of 3702

i am a shareholder.(in 4 a 1000 @ 3). purchase was made prior to joining thread. have been reading posts and wonder why the street loves to hate the stock, and why the company is unfriendly to shareholders. really doesn't make any sense whatsoever. i bought on source rec. w/o doing dd. based on what i'm reading it sounds like everybody has fallen in love w/ this co. not good from an investment standpoint for me. will continue to monitor, but not too optimistic.

To: EZLibra who wrote (785)	12/3/1997 6:41:00 PM
From: shero	Read Replies (1) \| Respond to of 3702

Wall Street always "overdoses" on one side or the other. You ask what TCLN might be worth. How about this scenario. I don't think its' impossible, or even far fetched. For sake of arguement bio-tech companies with successful products can trade at 10x sales. Assume 40,000,000 issued and out which gives plenty of leeway from the 28MM out now. Plenty of room for conversion of the last issuance and then some. Dr. Swift, from Hanifen, says TCLN might exceed $300,000,000 of U.S. sales from LYM-1. I'm going to assume $150,000,000 world wide sales, so if the drug is approved my estimate is conservative. I'm afraid to put the numbers in writing so multiply worldwide sales x 10 and divide by 40MM. That equals $30+per share and thats just for Lym-1. That doesn't include TNT, VE, VTA, and everything else we don't know about. That's enough to make me happy. Does that make you happy, too?